Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma

J Cutan Pathol. 2014 Nov;41(11):846-52. doi: 10.1111/cup.12383. Epub 2014 Oct 28.

Abstract

Background: High mitotic figure count (MFC) correlates with low survival rate in Merkel cell carcinoma (MCC). However, the prognostic impact of histone biomarkers as surrogates of MFC in MCC is unknown. We evaluated the prognostic significance of the immunodetection of mitotic figures and of G2+ tumor nuclei with histone-associated mitotic markers H3K79me3T80ph (H3KT) and phosphohistone H3 (PHH3) in MCC.

Methods: Immunohistochemical analyses of H3KT and PHH3 and proliferative marker Ki-67 were performed in a series of 21 cases of MCC. The significance of the pathologic data and immunoreactivity with these markers was evaluated with Pearson correlation and paired Student t-test. Univariate Cox proportional hazards regression models were performed to assess the relationships between these markers and survival.

Results: H3KT detected a higher number of mitotic figure (p<0.0001) and G2+ tumor nuclei (p<0.0052) than did PHH3. Furthermore, the MFC combined with G2+ tumor nuclei detected with H3KT compared to PHH3 and manual MFC was a significant predictor of impaired survival in patients with MCC (p=0.035; HR=1.0172), corresponding to a 1.72% increased risk of death for each unit increase in H3KT.

Conclusions: Biomarker analysis of proliferative rates with histone markers may have relevance in stratifying risk in patients with MCC.

Keywords: H3K79me3T80ph; Merkel cell carcinoma; PHH3; biomarker; histones.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Carcinoma, Merkel Cell / mortality
  • Carcinoma, Merkel Cell / pathology*
  • Cell Nucleus / pathology*
  • Cell Proliferation
  • Female
  • Histones / analysis*
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Mitosis
  • Prognosis
  • Proportional Hazards Models
  • Skin Neoplasms / mortality
  • Skin Neoplasms / pathology*

Substances

  • Biomarkers, Tumor
  • Histones